NCT00542464View on ClinicalTrials.gov

Multiple-Dose, Dose-Escalation Safety, Pharmacodynamics, and Pharmacokinetics Study of Imprime PGG™ Injection

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

May 31, 2006

Study Completion Date

September 30, 2006

Conditions

Healthy

Interventions

BIOLOGICAL

Imprime PGG TM for Injection

Doses of 1.0 mg/kg-4.0 mg/kg of Imprime PGG administered over 1-2 hr for 7 consecutive days

Sponsors

Lead Sponsor

HiberCell, Inc.

All Listed Sponsors

lead

HiberCell, Inc.

INDUSTRY

NCT00542464 - Multiple-Dose, Dose-Escalation Safety, Pharmacodynamics, and Pharmacokinetics Study of Imprime PGG™ Injection | Biotech Hunter | Biotech Hunter